#ASCO22 – Estudo de braço único fases 1-2 | Teclistamabe no mieloma múltiplo recidivante ou refratário.
13 Jun, 2022 | 14:38hTeclistamab in Relapsed or Refractory Multiple Myeloma – New England Journal of Medicine
Comentário no Twitter
MajesTEC-1: Teclistamab resulted in a high incidence of deep and durable response in patients with triple-class–exposed relapsed or refractory multiple myeloma. #ASCO22 https://t.co/Nanjob1q7p pic.twitter.com/oqfaiu8MOx
— NEJM (@NEJM) June 5, 2022